Back to results
US 2012/0258889 A1Published application
siRNA Targeting Kinase Insert Domain Receptor (KDR)
AssigneeDharmacon, Inc.
InventorsAnastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Life of this patent
Estimating the term…
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
Claims20
An siRNA molecule, wherein said siRNA molecule consists of:
- (a) a duplex region;
- and (b) either no overhang regions or at least one overhang region, wherein each overhang region contains six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region are each 19-30 nucleotides in length and said antisense region comprises a sequence that is the complement of a sequence selected from the group consisting of SEQ ID NO:
- 438-463, 465-556 and 558-622.
A chemically synthesized double stranded siRNA molecule, wherein:
- (a) each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length;
- and
- (b) one strand of said siRNA molecule comprises a sequence that is the complement of a sequence selected from the group consisting of SEQ ID NO:
- 438-463, 465-556 and 558-622.
1 more element
Dependencies are inferred from the claim text.